Approved to use minugh unit allow, Own De U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COM-U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMnder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10612975
Filing Date		2003-07-07
First Named Inventor	Micha	nel Redecker
Art Unit		2879
Examiner Name	Kevin	J. QUARTERMAN
Attorney Docket Number		6161.0066.US

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code! Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add	
-			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant R		Releva	Columns, Lines who ant Passages or Re s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button		
				FOREIG	GN PA1	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Examiner Cite Foreign Document Country Kind Code ⁴		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lin where Relevant Passages or Releva Figures Appear	76			
	1	2002-091380	JP			2002-03-27	Samsung SDI Co L	.td		
	2	2000-321994	JP			2000-11-24	Fujitsu Ltd			
	3	07-084532	JP			1995-03-31	Fuji Xerax Co Ltd			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10612975		
iling Date		2003-07-07		
irst Named Inventor Micha		el Redecker		
Art Unit		2879		
xaminer Name Kevin		J. QUARTERMAN		
Manager Darelant Mountain		6161 0066 US		

	4	2005-50208	6	JP		2005-01-20	Cambridge Display Technology Limited		
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journat, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T6		
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered								
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a									

See for Codes of USPTO Platent Documents at year, LIBETO,000 or MPEP 001.04. Feater office and issued for document, by the ho-letter code (WIPO Standard STI), 3. Feater office and the impact may be provided by self-in unless of the paper of the region of the Engerer many procedure the self-in unless of the paper of the region of the Engerer many procedure the self-in unless of the paper of the region of the Engerer many procedure the self-in unless of the Standard STI, 16 if possible. Supplicant is to place a check mark here fittingle insquare arrelation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10612975
Filing Date		2003-07-07
First Named Inventor Micha		ael Redecker
Art Unit		2879
Examiner Name Kevin		J. QUARTERMAN
Attorney Docket Number		6161,0066,US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information displacate statement. Con 27 CED 1 07(a)/1)

OR

	That no item of information contained in the information disclosure statement was cited in a communication from a
	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
	after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
_	any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
	statement. See 37 CFR 1.97(e)(2).

٦	See	attached	certification	statement.

Fee set forth in 3	7 CFR 1.17 (p) has been submitted herewith.

-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/hae-chan park/	Date (YYYY-MM-DD)	2006-12-22
Name/Print	Hae-Chan Park	Registration Number	50.114

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.